This is a working overview of carcinogenicity, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-02. Anything still debated is marked as such rather than presented as settled.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
C.D. Cone studied the role of resting potential in regulating cell differentiation and proliferation. Subsequent work has identified specific regions of the resting potential spectrum that correspond to distinct cell states such as quiescent, stem, cancer, and terminally differentiated. Although this body of work generated a significant amount of high-quality physiological data, this large-scale biophysics approach has historically come second to the study of biochemical gradients and genetic networks in biology education, funding, and overall popularity among biologists. A key factor that contributed to this field lagging behind molecular genetics and biochemistry is that bioelectricity is inherently a living phenomenon – it cannot be studied in fixed specimens. Working with bioelectricity is more complex than traditional approaches to developmental biology, both methodologically and conceptually, as it typically requires a highly interdisciplinary approach.
In 2011, food accounted for 70% of Indian retail, but was under-represented by organised retail. A.T. Kearney estimates India's organised retail had a 31% share in clothing and apparel, while the home supplies retail was growing between 20% and 30% per year. These data correspond to retail prospects prior to November announcement of the retail reform. It might be true that India has the largest number of shops per inhabitant. However, detailed figures are available for Belgium, the Netherlands, and Luxembourg. In Belgium, the number of outlets is approximately 8 per 1,000 inhabitants, while in the Netherlands it is 6 per 1,000 inhabitants. Therefore, the Indian figure must be significantly higher.
=== Toxins from the production of blue cheese === Penicillium roqueforti, responsible for the greenish blue moldy aspect of blue cheese, produces several mycotoxins. While mycotoxins like roquefortine, isofumigaclavine A, mycophenolic acid and ferrichrome are present at low levels, penicillic acid and PR toxin are unstable in the cheese. Because of the instability of PR toxin and lack of optimal environmental conditions (temperature, aeration) for the production of PR toxin and roquefortine, health hazards due to Penicillium roqueforti metabolites are considerably reduced. Additionally, mycotoxin contamination occurs at low levels and large quantities of cheese are rarely consumed, suggesting that hazard to human health is unlikely.
The Basuto Gun War, also known as the Basutoland Rebellion, was a conflict between the Basuto and the British Cape Colony. It lasted from 13 September 1880 to 29 April 1881 and ended in a Basuto victory. Following Basutoland's transformation into a British dominion on 12 March 1868, it became the target of rapid westernization efforts by the Cape Colony administration. In 1879, the Cape Parliament extended the Peace Preservation Act to Basutoland, with the aim of disarming the Basuto people. The immense significance of guns in Basuto society, compounded with past grievances, resulted in a rebellion led by chiefs Lerotholi and Masopha, which erupted on 13 September 1880. Heavily outnumbered and stretched thin by the simultaneous outbreak of other revolts, the Cape Colonial Forces failed to achieve a decisive military victory. The ensuing military stalemate and the high cost of conducting the war in made it increasingly unpopular among Cape politicians. On 29 April 1881, High Commissioner for Southern Africa, Sir Hercules Robinson announced the peaceful settlement of the conflict. The Cape's subsequent efforts to enforce disarmament and re-establish the rule of law in Basutoland met with stiff resistance from Masopha and his supporters. Unable to control the Basuto, the Cape Parliament passed the Disannexation Act in September 1883. The Basuto Gun War represents a rare example of an African nation's military victory against a colonial power, whereby the Basuto were able to retain their guns.
Hookah, Sasuba and Snuba systems are categorised as "air-line" equipment, as they do not include the communication, lifeline and pneumofathometer hose characteristic of a full diver's umbilical. Most hookah diving uses a demand system based on a standard scuba second stage, but there have been special purpose free-flow full-face masks specifically intended for hookah diving (see photos). A bailout system, or emergency gas supply (EGS) is not an inherent part of an air-line diving system, though it may be required in some applications. Their field of application is very different from full surface-supplied diving. Hookah is generally used for shallow water work in low-hazard applications, such as archaeology, aquaculture, and aquarium maintenance work, but is also sometimes used for open water hunting and gathering of seafood, shallow water mining of gold and diamonds in rivers and streams, and bottom cleaning and other underwater maintenance of boats. Sasuba and Snuba are mainly a shallow water recreational application for low-hazard sites. Sasuba and hookah diving equipment is also used for boat maintenance and hull cleaning, swimming pool maintenance, and shallow underwater inspections. The systems used to supply air through the hose to a demand valve mouthpiece, are either 12-volt electrical air pumps, gasoline engine powered low-pressure compressors, or floating scuba cylinders with high pressure regulators. These hookah diving systems usually limit the hose length to allow less than 7 metres depth.
Sources: en.wikipedia.org
Barbara Seliger Larsen is a mass spectrometrist, with a career in instrumentations and applications of mass spectrometry in industry, and served on the board of the American Society for Mass Spectrometry for several terms.
=== Dispute with Vivendi === On September 20, 2004, GameSpot reported that Sierra's parent company, Vivendi Universal Games, was in a legal battle with Valve over the distribution of Half-Life 2 to cyber cafés. Cyber cafés were important for the gaming market in Asia, where PC and broadband penetration per capita were much lower in most territories. According to Vivendi, the distribution contract they signed with Valve included cyber cafés. This would mean that only Vivendi could distribute Half-Life 2 to cyber cafés — not Valve through the Steam system. On November 29, 2004, Judge Thomas S. Zilly, of U.S. Federal District Court in Seattle, Washington, ruled that Vivendi and its affiliates were not authorized to distribute (directly or indirectly) Valve games through cyber cafés for pay-to-play activities according to the parties' current publishing agreement. Zilly also ruled in favor of the Valve motion regarding the contractual limitation of liability, allowing Valve to recover copyright damages for any infringement as allowed by law without regard to the publishing agreement's limitation of liability clause. On April 29, 2005, Valve and Vivendi announced a settlement. Vivendi would cease distributing all retail packaged versions of Valve games by August 31, 2005. Vivendi was also to notify distributors and cyber cafés that had been licensed by Vivendi that only Valve had the authority to distribute cyber café licenses; their licenses were revoked and switched to Valve's.
=== Elderly === Valproate may cause increased somnolence in the elderly. In a trial of valproate in elderly patients with dementia, a significantly higher portion of valproate patients had somnolence compared to placebo. In approximately one-half of such patients, there was associated reduced nutritional intake and weight loss.
This property is what gives DNA its semi-conservative nature where one strand of new DNA is from an original parent strand. Although the structure of DNA showed how inheritance works, it was still not known how DNA influences the behavior of cells. In the following years, scientists tried to understand how DNA controls the process of protein production. It was discovered that the cell uses DNA as a template to create matching messenger RNA, molecules with nucleotides very similar to DNA. The nucleotide sequence of a messenger RNA is used to create an amino acid sequence in protein; this translation between nucleotide sequences and amino acid sequences is known as the genetic code. With the newfound molecular understanding of inheritance came an explosion of research. A notable theory arose from Tomoko Ohta in 1973 with her amendment to the neutral theory of molecular evolution through publishing the nearly neutral theory of molecular evolution. In this theory, Ohta stressed the importance of natural selection and the environment to the rate at which genetic evolution occurs. One important development was chain-termination DNA sequencing in 1977 by Frederick Sanger. This technology allows scientists to read the nucleotide sequence of a DNA molecule. In 1983, Kary Banks Mullis developed the polymerase chain reaction, providing a quick way to isolate and amplify a specific section of DNA from a mixture. The efforts of the Human Genome Project, Department of Energy, NIH, and parallel private efforts by Celera Genomics led to the sequencing of the human genome in 2003.
The conflict is commonly referred to simply as "the Boer War" because the First Boer War (1880–81) was much smaller. Boer (meaning "farmer") is the common name for Afrikaans-speaking white South Africans descended from the Dutch East India Company's settlers at the Cape of Good Hope. Among some South Africans, it is known as the (Second) Anglo–Boer War. In Afrikaans, it is called the 'Tweede Vryheidsoorlog ("Second Freedom War"), 'Tweede Boereoorlog ("Second Boer War"), Anglo–Boereoorlog ("Anglo–Boer War") or Engelse oorlog ("English War"). In South Africa, it is officially called the South African War. According to a 2011 BBC report, "most scholars prefer to call the war of 1899–1902 the South African War, thereby acknowledging that all South Africans, white and black, were affected by the war and that many were participants".
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.